$CATX News

Perspective Therapeutics doses first brain tumor patient in expanded radiopharmaceutical trial

Perspective Therapeutics Expands Therapeutic Focus Areas; First Patient Dosed with [212Pb]VMT-α-NET in the Meningioma Cohort of a Phase 1/2a Study

Perspective Doses First Brain Tumor Patient in Radiopharmaceutical Study, Expands Cancer Drug Trial to Meningioma Patients

Perspective Therapeutics to Present Data from All Clinical Programs at the 2026 ASCO Annual Meeting, including Findings from [212Pb]VMT01 in Melanoma

Perspective Therapeutics Reports Early Response SignalS And Favorable Safety Across Three Radiopharmaceutical Programs At ASCO 2026, Including 29% Response Rate In Advanced Melanoma Cohort

Perspective Therapeutics Announces First Patients Dosed in New Cohorts of Two Ongoing Phase 1/2a Studies

Perspective Therapeutics Announces That The First Patients Were Dosed In Two New Cohorts Of Phase 1/2a Studies In Neuroendocrine Tumors And Solid Tumors, Respectively

Perspective Therapeutics, Inc. (CATX) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Perspective Therapeutics (NYSEARCA:CATX) Posts Mixed Q1 2026 Results, EPS Beat and Revenue Miss

Perspective Therapeutics Provides Recent Business Highlights and Reports 1Q 2026 Results

Perspective Therapeutics Q1 EPS $(0.25) Beats $(0.31) Estimate, Sales $76.000K Miss $136.917K Estimate

Wedbush Reiterates Outperform on Perspective Therapeutics, Maintains $11 Price Target

BTIG Reiterates Buy on Perspective Therapeutics, Maintains $14 Price Target

Perspective Therapeutics, Inc. (CATX) Shareholder/Analyst Call - Slideshow

Perspective Therapeutics: Decent Prospect In Radiopharmaceuticals Field

Perspective Therapeutics to Provide Several Upcoming Corporate Updates

Perspective Therapeutics Presents Updated Interim Data of [212Pb]VMT-α-NET in Its Ongoing Phase 1/2a Clinical Trial at the 2026 AACR Annual Meeting

Perspective Therapeutics shares are trading higher after the company announced updated interim results from its ongoing Phase 1/2a clinical trial of VMT-α-NET in patients with unresectable or metastatic somatostatin receptor type 2 expressing neuroendocrine tumors as part of a poster presentation at the American Association for Cancer Research Annual Meeting 2026.

Perspective Therapeutics shares are trading higher after the company announced updated interim results from its ongoing Phase 1/2a clinical trial of VMT-α-NET in patients with unresectable or metastatic somatostatin receptor type 2 expressing neuroendocrine tumors as part of a poster presentation at the American Association for Cancer Research Annual Meeting 2026.

Wedbush Reiterates Outperform on Perspective Therapeutics, Maintains $11 Price Target